GSKNYSEPharmaceutical PreparationsAlso trades as GLAXF
GSK plc
Financials through fiscal 2025, year ended Dec 31, 2025
$49.46−0.05 (-0.10%)
Close on Oct 19, 2026
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
347M
Shares held, 13F filers
Institutional holders
1,036
108 new, 81 sold out
Net institutional buying
-27M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 369,576,114 | 8.90% | 13G (passive) amendment | Dec 31, 2024 |
| Abigail P. Johnson | 234,936,061 | 5.80% | 13G (passive) | Mar 31, 2026 |
| GSK plc | 1,983,025 | 9.50% | 13D (active) amendment | Nov 12, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of GSK | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 64,961,641 | – | $3.41B | −2,700,005 | 0.15% |
| Dodge & Cox | 48,197,514 | – | $2.53B | −10,465,460 | 1.32% |
| Fisher Asset Management, LLC | 35,722,792 | – | $1.87B | +1,200,429 | 0.56% |
| Primecap Management Co/Ca/ | 25,182,068 | – | $1.32B | −22,470 | 0.78% |
| Wellington Management Group Llp | 11,396,249 | – | $597.39M | −321,364 | 0.10% |
| JTC Employer Solutions Trustee Ltd | 8,592,987 | – | $450.32K | −449,402 | 36.11% |
| Morgan Stanley | 7,657,562 | – | $401.41M | −3,373,089 | 0.02% |
| Royal Bank of Canada | 7,588,928 | – | $397.81M | +82,142 | 0.06% |
| Price T Rowe Associates Inc /Md/ | 6,923,642 | – | $362.94K | −399,191 | 0.04% |
| Acadian Asset Management LLC | 6,660,434 | – | $349.11K | −5,136,651 | 0.41% |
| Goldman Sachs Group Inc | 6,371,442 | – | $333.99M | −3,217,672 | 0.03% |
| State Street Corp | 5,959,115 | – | $315.14M | −39,371 | 0.01% |
| Mondrian Investment Partners LTD | 4,910,830 | – | $257.43M | −76,563 | 3.97% |
| Bank Of Montreal /Can/ | 4,042,863 | – | $211.93M | −596,936 | 0.07% |
| BlackRock, Inc. | 3,620,294 | – | $189.78M | +69,390 | 0.00% |
| Grantham, Mayo, Van Otterloo & Co. LLC | 3,599,521 | – | $188.69M | +76,955 | 0.42% |
| Hotchkis & Wiley Capital Management LLC | 3,413,574 | – | $178.94M | −68,480 | 0.52% |
| Equity Investment Corp | 3,269,765 | – | $171.40M | +48,730 | 3.27% |
| UBS Group AG | 2,806,205 | – | $147.10M | +721,970 | 0.02% |
| Connor, Clark & Lunn Investment Management Ltd. | 2,767,591 | – | $145.08M | −49,854 | 0.27% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|
| Q2 2026 | 1,036 | 347M | 108 / 376 | 340 / 81 | 17M | 44M |
| Q1 2026 | 1,031 | 374M | 139 / 315 | 382 / 83 | 31M | 52M |
| Q4 2025 | 993 | 398M | 179 / 309 | 338 / 61 | 41M | 31M |
| Q3 2025 | 892 | 388M | 100 / 323 | 307 / 79 | 27M | 25M |
| Q2 2025 | 887 | 386M | 111 / 367 | 252 / 62 | 44M | 17M |
| Q1 2025 | 854 | 365M | 91 / 330 | 277 / 67 | 52M | 28M |
| Q4 2024 | 844 | 341M | 110 / 284 | 317 / 149 | 68M | 35M |
| Q3 2024 | 894 | 309M | 91 / 304 | 319 / 69 | 24M | 26M |
| Q2 2024 | 879 | 312M | 78 / 307 | 304 / 87 | 25M | 49M |
| Q1 2024 | 901 | 336M | 98 / 326 | 298 / 79 | 56M | 19M |
| Q4 2023 | 889 | 300M | 127 / 270 | 341 / 63 | 37M | 22M |
| Q3 2023 | 842 | 285M | 100 / 303 | 268 / 70 | 26M | 17M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of GSK | Value | % of fund | As of |
|---|---|---|---|---|---|
| Dodge & Cox Stock Fund | 35,573,787 | – | $1.86B | 1.58% | Jun 30, 2026 |
| Vanguard Primecap Fund | 18,172,650 | – | $952.61M | 0.99% | Jun 30, 2026 |
| Vanguard Wellington Fund | 9,662,999 | – | $488.37M | 0.39% | May 31, 2026 |
| Strategic Advisers Fidelity U.S. Total Stock Fund | 7,787,127 | – | $393.56M | 0.16% | May 31, 2026 |
| Fidelity Series Large Cap Stock Fund | 4,579,628 | – | $240.06M | 0.83% | Jun 30, 2026 |
| Fidelity Series Value Discovery Fund | 4,136,200 | – | $213.80M | 1.21% | Jul 31, 2026 |
| Dodge & Cox Balanced Fund | 3,600,595 | – | $188.74M | 1.28% | Jun 30, 2026 |
| Vanguard Primecap Core Fund | 3,549,080 | – | $186.04M | 1.03% | Jun 30, 2026 |
| Fidelity Growth and Income Portfolio | 3,439,475 | – | $177.79M | 1.19% | Jul 31, 2026 |
| Fidelity Equity Dividend Income Fund | 2,665,900 | – | $134.73M | 1.67% | May 31, 2026 |
| T. Rowe Price International Value Equity Fund | 2,639,571 | – | $136.44M | 0.80% | Jul 31, 2026 |
| Select Pharmaceuticals Portfolio | 2,425,160 | – | $122.57M | 8.17% | May 31, 2026 |
| Bridge Builder Large Cap Value Fund | 1,876,800 | – | $98.38M | 0.34% | Jun 30, 2026 |
| Fidelity Large Cap Stock Fund | 1,708,759 | – | $88.33M | 0.83% | Jul 31, 2026 |
| Vanguard Windsor Ii Fund | 1,597,215 | – | $82.56M | 0.12% | Jul 31, 2026 |
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Maria E. Martinez Officer | Aug 20, 2026 | 44,397 | $2.31M | Aug 20, 2026 | Share Value Plan Vesting |